Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in...

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• RAS pathway mutations are found in 30% of chronic myelomonocytic leukemia (CMML) patients.
• These mutations are associated with resistance to hypomethylating agent (HMA) therapy, the current standard of care.
• Understanding the mechanisms of RAS-mutated CMML is crucial for developing effective treatments.

Purpose of the Study:

• To dissect the biological mechanisms driving the initiation and progression of RAS pathway-mutated CMML.
• To investigate the role of inflammatory signaling in disease pathogenesis.
• To identify therapeutic targets for improving patient survival.

Main Methods:

• Utilized single-cell, multi-omics technologies to analyze patient samples.
• Investigated transcriptional reprogramming in hematopoietic stem and progenitor cells (HSPCs) and monocytic populations.
• Examined the role of the NF-κB pathway and MCL1 in HSPC survival and expansion.

Main Results:

• RAS pathway mutations induce transcriptional reprogramming in HSPCs and monocytic cells.
• Inflammatory signaling contributes to disease progression and impairs immune cell function.
• HSPCs expand post-therapy (HMA or venetoclax) and depend on MCL1 for survival.

Conclusions:

• RAS pathway mutations fundamentally alter cellular signaling in CMML.
• Therapeutic strategies targeting MCL1 may be beneficial for RAS-mutated CMML.
• Further research into inflammatory pathways and HSPC regulation is warranted for improved CMML treatment.